• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小肝细胞癌的病理形态学特征:特别提及边界不清的小肝细胞癌。

Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins.

作者信息

Nakashima O, Sugihara S, Kage M, Kojiro M

机构信息

First Department of Pathology, Kurume University School of Medicine, Japan.

出版信息

Hepatology. 1995 Jul;22(1):101-5.

PMID:7601399
Abstract

Some surgically resected small hepatocellular carcinoma (HCC) up to 2 cm in diameter have indistinct margins, and it is sometimes difficult to identify the margins of the cancer nodule in the resected specimen. We classified such tumors as small HCC with indistinct margins and carried out a morphological study to define their characteristics in comparison with small HCC with distinct margins as a control group. We have encountered 27 examples among 86 tumors smaller than 2.0 cm in diameter. The tumors of this type indistinctly retained the basic architecture of the background and were vaguely demarcated. Most tumors were uniformly composed of well-differentiated cancer tissue, which is characterized by increased cell density with increased nuclear/cytoplasm ratio, increased cytoplasmic eosinophilia, and irregular thin-trabecular pattern with occasional pseudoglandular pattern. Portal tracts were included within the cancerous tissue. There was a "replacing" growth pattern at the tumor/nontumor boundary. Four of the 27 lesions had a nodule-in-nodule appearance, and the inner nodules consisted of moderately differentiated HCC without portal tracts. In all of the small HCC with indistinct margins, tumor invasion into the portal vein and intrahepatic metastasis were not found. In a control group, the tumors were well-demarcated, and 53% of them were encapsulated. They were well-differentiated in 9, moderately differentiated in 38 and mixed well and moderately in 12. Tumor invasion into the portal vein and intrahepatic metastasis was found in 16 (27.1%) and 6 (10.2%), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

一些手术切除的直径达2厘米的小肝细胞癌(HCC)边界不清,有时在切除标本中难以识别癌结节的边界。我们将此类肿瘤归类为边界不清的小HCC,并进行了形态学研究以确定其特征,并与边界清晰的小HCC作为对照组进行比较。在86个直径小于2.0厘米的肿瘤中,我们遇到了27个此类病例。这种类型的肿瘤模糊地保留了背景的基本结构,边界模糊。大多数肿瘤由高分化癌组织均匀组成,其特征为细胞密度增加、核/质比增加、细胞质嗜酸性增强,以及不规则的细小梁模式,偶尔有假腺管模式。癌组织内包含门静脉分支。肿瘤/非肿瘤边界处有“替代”生长模式。27个病灶中有4个呈结节内结节外观,内部结节由无门静脉分支的中分化HCC组成。在所有边界不清的小HCC中,均未发现肿瘤侵犯门静脉和肝内转移。在对照组中,肿瘤边界清晰,其中53%有包膜。高分化的有9个,中分化的有38个,高分化与中分化混合的有12个。分别有16个(27.1%)和6个(10.2%)发现肿瘤侵犯门静脉和肝内转移。(摘要截取自250字)

相似文献

1
Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins.小肝细胞癌的病理形态学特征:特别提及边界不清的小肝细胞癌。
Hepatology. 1995 Jul;22(1):101-5.
2
[Pathomorphologic characteristics and differential diagnosis of small hepatocellular carcinoma].小肝细胞癌的病理形态学特征及鉴别诊断
Gan To Kagaku Ryoho. 1996 Jun;23(7):827-34.
3
Pathology of early hepatocellular carcinoma: progression from early to advanced.早期肝细胞癌的病理学:从早期到晚期的进展
Hepatogastroenterology. 1998 Aug;45 Suppl 3:1203-5.
4
'Nodule-in-nodule' appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation.
Intervirology. 2004;47(3-5):179-83. doi: 10.1159/000078470.
5
N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.N- myc下游调控基因1(NDRG1)/ Cap43增强人肝细胞癌的门静脉侵犯和肝内转移。
Oncol Rep. 2008 Dec;20(6):1329-35.
6
Multistep, multicentric, and simultaneous development of hepatocellular carcinoma.肝细胞癌的多步骤、多中心及同时发生发展
Am J Gastroenterol. 1993 Oct;88(10):1770-2.
7
Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.手术切除的小肝细胞癌中甲胎蛋白及维生素K缺乏或拮抗剂II诱导蛋白表达的免疫组织学研究
Hepatology. 2001 Dec;34(6):1128-34. doi: 10.1053/jhep.2001.29202.
8
Prognosis of well differentiated small hepatocellular carcinoma--is well differentiated hepatocellular carcinoma clinically early cancer?高分化小肝细胞癌的预后——高分化肝细胞癌在临床上属于早期癌症吗?
Hepatogastroenterology. 1995 Nov-Dec;42(6):923-30.
9
Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma.血管内皮生长因子-C在人肝细胞癌中的表达
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):152-60. doi: 10.1111/j.1440-1746.2005.04217.x.
10
Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors.肝细胞癌的组织病理学评估,特别涉及早期小肿瘤。
Semin Liver Dis. 1999;19(3):287-96. doi: 10.1055/s-2007-1007118.

引用本文的文献

1
Contrast-enhanced ultrasound findings of hepatic pseudolipoma: a case report.肝假性脂肪瘤的超声造影表现:一例报告
Front Oncol. 2025 Aug 1;15:1581523. doi: 10.3389/fonc.2025.1581523. eCollection 2025.
2
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.亚洲肿瘤消融治疗肝细胞癌指南会议
Liver Cancer. 2025 Mar 3:1-27. doi: 10.1159/000544976.
3
Feasibility of large language models for CEUS LI-RADS categorization of small liver nodules in patients at risk for hepatocellular carcinoma.大语言模型用于肝细胞癌高危患者小肝结节的CEUS LI-RADS分类的可行性
Front Oncol. 2024 Dec 18;14:1513608. doi: 10.3389/fonc.2024.1513608. eCollection 2024.
4
Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular Carcinoma.蛋白激酶Cδ是肝细胞癌的一种新型生物标志物。
Gastro Hep Adv. 2022 Aug 5;2(1):83-95. doi: 10.1016/j.gastha.2022.07.020. eCollection 2023.
5
Vessel co-option: a unique vascular-immune niche in liver cancer.血管共选择:肝癌中一种独特的血管免疫微环境
Front Oncol. 2024 Apr 26;14:1386772. doi: 10.3389/fonc.2024.1386772. eCollection 2024.
6
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.免疫疗法与肝移植:基础与临床数据的叙述性综述
Cancers (Basel). 2023 Sep 15;15(18):4574. doi: 10.3390/cancers15184574.
7
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.肝细胞癌切除或消融术后辅助使用阿替利珠单抗-贝伐珠单抗
Liver Cancer. 2023 May 24;12(3):189-197. doi: 10.1159/000531225. eCollection 2023 Aug.
8
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma.肝细胞癌根治性治疗后辅助使用阿替利珠单抗-贝伐珠单抗。
Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):435-439. doi: 10.21037/hbsn-23-203. Epub 2023 May 22.
9
Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.联合局部消融与免疫治疗肝细胞癌:原理、疗效与展望。
Front Immunol. 2022 Nov 23;13:1033000. doi: 10.3389/fimmu.2022.1033000. eCollection 2022.
10
Tumor vessel co-option: The past & the future.肿瘤血管共选:过去与未来
Front Oncol. 2022 Aug 31;12:965277. doi: 10.3389/fonc.2022.965277. eCollection 2022.